Clinical Trial Update: Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Pfizer-sponsored study evaluating biomarkers in relapsed/refractory pediatric solid tumors completed. Results were posted January 11, 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Neoplasms

Snippet

Sponsor: Pfizer | Conditions: Adenocarcinoma, Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-01-11